Biocytogen signs Antibody Agreement with ADC Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) recently announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. […]
Biocytogen and LiberoThera reach landmark in development of Fully Human GPCR Antibody Drugs
US based Biocytogen Pharmaceuticals entered a strategic collaboration with Japan headquartered LiberoThera to co-develop fully human GPCR antibodies using Biocytogen’s advanced antibody discovery platform based on fully human antibody RenMab mice combined with LiberoThera’s outstanding membrane antigen preparation technology. In around a year since the collaboration was established, the two parties have reportedly screened out a […]
